Rubio, Jose M. http://orcid.org/0000-0002-0056-4135
Lencz, Todd http://orcid.org/0000-0001-8586-338X
Cao, Hengyi http://orcid.org/0000-0003-4168-0391
Kraguljac, Nina
Dhamala, Elvisha
Homan, Philipp http://orcid.org/0000-0001-9034-148X
Horga, Guillermo
Sarpal, Deepak K. http://orcid.org/0000-0001-5842-6782
Argyelan, Miklos http://orcid.org/0000-0002-7254-1776
Gallego, Juan http://orcid.org/0000-0003-4900-7812
Cholewa, John
Barber, Anita
Kane, John M.
Malhotra, Anil K.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K23MH127300)
Article History
Received: 19 July 2023
Revised: 6 December 2023
Accepted: 13 December 2023
First Online: 4 January 2024
Competing interests
: JR has received research support from Alkermes, speaker bureau or advisory board compensation from TEVA, Karuna, Janssen, royalties from UpToDate. PH has received grants and honoraria from Novartis, Lundbeck, Mepha, Janssen, Boehringer Ingelheim, Neurolite outside of this work. JK has received funds for research support from H. Lundbeck, Janssen, and Otsuka; has received consulting fees or honoraria for lectures from Alkermes, Biogen, Boehringer Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HLS, Indivior, Intra-Cellular Therapies, Janssen, Johnson and Johnson, Karuna, LB Pharmaceuticals, Merck, Minerva, Neurocrine, Neumora, Newron, Novartis, Otsuka, Reviva, Roche, Saladax, Sunovion, Takeda, and Teva; and has ownership interest in HealthRhythms, North Shore Therapies, LB Pharmaceuticals, Medincell, and the Vanguard Research Group. The rest of the authors declare no conflict of interest.